Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study - Willett, Christopher G.; Duda, Dan G.; di Tomaso, Emmanuelle; Boucher, Yves; Ancukiewicz, Marek; Sahani, Dushyant V.; Lahdenranta, Johanna; Chung, Daniel C.; Fischman, Alan J.; Lauwers, Gregory Y.; Shellito, Paul; Czito, Brian G.; et al. (Journal of clinical oncology, 2009)
Keywords: Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic - administration & dosage; Bevacizumab; Biological and medical sciences; Biomarkers - blood; Cmod; Combined Modality Therapy; Endothelial Cells - cytology; Female; Fluorouracil - administration & dosage; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Interleukin-6 - blood; Male; Medical sciences; Middle Aged; Neoadjuvant Therapy; Original Reports; Radn; Rectal Neoplasms - mortality; Rectal Neoplasms - radiotherapy; Rectal Neoplasms - surgery; Rectal Neoplasms - therapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Vascular Endothelial Growth Factor A; Antineoplastic agent; Rectal disease; Biological marker; Monoclonal antibody; Neoadjuvant treatment; Bevacizumab; Cancerology; Phase II trial; Intestinal disease; Antiangiogenic agent; Anorectal disease; Multidisciplinary; Fluorouracil; Enzyme; Fluoropyrimidine derivatives; Transferases; Treatment efficiency; Enzyme inhibitor; Malignant tumor; Rectum cancer; Thymidylate synthase; Radiotherapy; Vascular endothelium growth factor; Antimetabolic; Methyltransferases; Pyrimidine derivatives; Digestive diseases; Cancer